Tauopathies are a group of neurodegenerative disorders that include Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and other related diseases with prominent tau pathology. Research advances in the last several decades have characterized and defined tau neuropathologies of both neuron and glia in these diverse disorders and this has stimulated development of animal models of tauopathies. Indeed, animal models ranging from invertebrate species such as C. elegan to Drosophila melanogaster and mammalian transgenic mouse models of tauopathies have been generated and reported. This review summarizes the salient features of many of the known models of tauopathies. D
Introduction
Most common neurodegenerative diseases are characterized by proteinaceous, filamentous inclusions of nerve cells of the brain [19] . In several neurodegenerative diseases, including hereditary frontotemporal dementias (FTDs) such as FTD with parkinsonism linked to chromosome 17 , as well as sporadic variants of FTDs like progressive supranuclear palsy (PSP), and Pick's Disease, tau protein accumulates as intracellular neurofibrillary tangles (NFTs) [28] . For this reason, these disorders are classified as tauopathies and the prominence of tau pathologies therein has been taken to imply that tau abnormalities are linked to mechanisms of brain degeneration in tauopathies. In Alzheimer's disease (AD), hyperphosphorylated tau forms the paired helical filaments (PHFs) in NFTs, and it associates with h-amyloid (Ah) in the dystrophic neurites surrounding the characteristic amyloid plaques formed by fibrillar deposits of Ah [9, 29] . Mutations in the tau gene are pathogenic for FTDP-17 and the discovery of these disease causing mutations therefore established the central role of tau dysfunction in neurodegenerative diseases [30] . The mechanism of tau dysfunction in neurodegeneration, however, is not understood. Hypotheses based on clinical evidence abound, including disrupted axonal transport, toxicity of aggregated tau protein, and the phosphorylation state of tau [19] .
Tau is a microtubule-associated protein (MAP) that is widely expressed in the mammalian nervous system, where it regulates the stability and assembly of microtubules. In the adult human brain, six tau isoforms are produced by alternative mRNA splicing. Mutations of tau that are associated with FTDP-17 are missense, deletion, or silent mutations. These mutations can influence tau either [1] at the mRNA level, changing the alternative splicing of tau and thus the relative tau isoform ratio, or [2] at the protein level, changing the binding characteristics of tau with microtubules or by increasing assembly of tau into filaments [19] .
A variety of animal models of tauopathies have been created to explore the mechanism of tau dysfunction in neurodegenerative disease. To date, these models span the phylogenetic tree and include Caenorhabditis elegans, Drosophila melanogaster, Xenopus oocytes, and, of course, the mouse. 
C. elegans
Invertebrate models of disease offer some advantages when compared to vertebrate models, especially in early stages of discovery of gene interactions and tissue-level effects. C. elegans models, in particular, are easily genetically manipulated, mature rapidly, and can be utilized to screen pharmacological compounds. C. elegans is very well characterized at every level and is an excellent model for inquiry into both wild-type function and pathogenic dysfunction of proteins [23] .
Kraemer et al. [18] generated a transgenic C. elegans model of FTDP-17. Expression of wild-type human tau or forms of human tau with mutations associated with FTDP-17 (V337M and P301L) in nerve cells resulted in a degenerative phenotype. Degeneration was more pronounced in C. elegans lines that expressed FTDP-17-associated tau mutants compared to lines expressing wildtype tau. Transgenic tau was detected in most if not all neurons in the head as well as the dorsal and ventral nerve cords and in both cell bodies and neurites.
Expression of wild-type tau as a transgene in C. elegans caused decreased life span, uncoordinated locomotion, reduced egg laying, and dumpiness. Uncoordinated behavior was noticeable soon after hatching and became more pronounced with maturation. Uncoordinated locomotion culminated at 9 days when the worms became nearly immobile. Both of the C. elegans lines with tau mutations associated with FTDP-17 were more severely affected than the wild-type tau transgenic lines in the behavioral phenotypes.
The expression of tau in C. elegans causes defects at the cellular level. Expression of tau impaired cholinergic neurotransmission at the presynaptic stage, though postsynaptic transmission remained intact. The lines with tau mutations associated with FTDP-17 were more impaired in presynaptic cholinergic neurotransmission than C. elegans that expressed wild-type tau.
Tau that accumulates in the brains of human tauopathy subjects is insoluble to detergent extraction. In the C. elegans model, all transgenic lines produced soluble tau in approximately equivalent amounts, though the lines that expressed tau mutations associated with FTDP-17 produced more detergent-insoluble tau than lines that expressed wildtype tau. In one line that expressed the V377M tau mutant, the appearance of insoluble tau temporally coincided with the increasing severity of the behavioral deficit. It should also be noted that tau expressed in C. elegans is phosphorylated at many of the same sites as seen in authentic human tauopathies.
Tau expression caused axonal degeneration and neuronal loss in several of these worm models. By examining individual worms at various time points, the authors showed that the degenerative changes were progressive. By 7 days, the dorsal and ventral nerve cords evidenced multiple gaps (Fig. 1) . In addition, in animals that expressed FTDP-17-associated mutant tau, abnormal degenerating axons contained spherical aggregates and showed collapse of axonal membranes and the intra-axonal compartment. The line with the most extensive axonal degradation was the line that expressed the FTDP-17-associated mutant V337M of tau at late time points. This is the line that had the highest level of insoluble tau. While tau aggregation may or may not be required for the initial events of neurodegeneration, it does appear to contribute to the degenerative process that causes eventual neuronal loss [18] .
D. melanogaster
After the simplicity of the C. elegans system, the complexity of a fruit fly is a step forward in avenues of inquiry into neurodegenerative disease. Indeed, the Drosophila model offers many avenues for insight as an inter- [2, 27] . Many Drosophila models of neurodegenerative disease use the fly eye for directed expression studies. The fly retina is comprised of approximately 800 identical unit eyes, called ommatidia, and they are arranged in a hexagonal array to compose the adult eye. This repeated, highly regular structure amplifies minor perturbations in cell patterning, and degenerative changes in the eye can be measured over the adult life span of the fly. The cellular architecture of the Drosophila retina is also well characterized, and many imaging techniques and antibody reagents are available to probe underlying defects associated with degenerative phenotypes. Finally, the fly eye is completely dispensable for survival and for fertility in laboratory strains of Drosophila, and this facilitates genetic studies of neurodegenerative disease mechanisms. To illustrate, when the pathogenic form of the protein responsible for Machado-Joseph disease (MJD) is expressed in the fly eye, the expanded polyglutamine protein induces a progressive loss of pigmentation and neuronal integrity. When expressed more broadly in the entire nervous system, the expanded polyglutamine protein confers early lethality when strongly expressed, or adult mortality with the flies showing tremors and a loss of coordination in systems with lower expression levels [16, 24] . Because at least 50% of Drosophila genes have human homologs, and because upward of 70% of human disease genes have Drosophila homologs, the fly model and especially the fly-eye model are increasingly powerful tools to elucidate mechanisms of neurodegenerative diseases [2, 5, 12] .
D. melanogaster possess a single endogenous tau gene, but mutations have not yet been discovered at this locus in the fly. The fly tau gene is expressed in many neuronal cell types and the tau protein accumulates in axonal processes, as is the case with mammalian tau [12] . In one study, overexpression of the human tau homolog in various neuronal settings, including all neurons and cholinergic neurons, induced apoptotic neuronal cell death [8] . Retinal overexpression of tau in the fly-eye model causes a dramatically reduced and roughened eye [2] .
In both of these studies, the observed neuronal cell loss was not accompanied by the formation of intracellular NFTs, a hallmark of tauopathies [2, 8] . This surprising result suggests that tau-linked neurodegeneration may precede or occur independently of filamentous tau deposition, although tau aggregation was seen. Thus, fly tau models challenge accepted views of the role of intracellular tau-rich NFTs in human tauopathies, and this may implicate smaller tau aggregates in neuronal dysfunction and death. Indeed, it is possible that Drosophila models of tauopathies might be particularly amenable to analysis of early, pre-tangle events of tau-associated neurodegeneration.
Furthermore, Wittman et al. [36] report that a mutant of tau associated with a familial human tauopathy (R406W) is much more effective than wild-type tau in inducing neuronal apoptosis, and that flies expressing the FTDP-17 mutant shortened fly life span more severely than did wild-type tau expression [36] . In contrast, Jackson et al. [17] report that R406W mutant and wild-type human tau are equally potent, implying that tau overexpression per se is neurotoxic, perhaps through a dominant negative effect. In addition, though neither of these studies found intracellular NFTs, both found tau to be hyperphosphorylated on residues reminiscent of those in human tauopathies and tangles, thus decoupling tau hyperphosphorylation and tangle formation. Indeed, hyperphosphorylated and conformationally altered transgenic tau progressively accumulated in the brains of aged flies in these two studies, bearing a resemblance to fibrillar tau associated with human tauopathies when visualized by electron microscopy. These studies did not exclude the possibility of infrequent NFTs, scattered tau filaments, tau protofibril or other mis-folded/aggregated species of tau that might have deleterious effects on cellular function [17] .
Fly tau studies are not without contradictory results. Wittman et al. [36] reported normal brain tissue volume and organization of major neuronal projection systems in young adult transgenic tau and tau mutant flies when the tau was expressed in a panneural pattern. In aged flies, however, the cortex was rife with vacuolization and neuronal degeneration. It must also be noted that neither wild-type nor mutant tau overexpression in cholinergic neurons shortened fly life span [36] . Another study, however, described substantial morphological changes in sensory neurons in adult flies expressing human tau or tau-fusion proteins, such as abnormal axon bundling, reduced terminal arborizations, loss of axons, and axonal swelling [35] .
One study, however, observed intracellular NFT-like structures in a fly model. In this system, human tau was coexpressed with shaggy, the fly homolog of glycogen synthetase kinase-3h (GSK-3h). Coexpression of these two proteins produced not only NFTs but also enhanced neurodegeneration. GSK-3h is a central component of the developmental Wnt signaling pathway. In the fly model, GSK-3h phosphorylates tau on the same residues associated with tau hyperphosphorylation observed in AD and FTDP-17 cases. Jackson et al. [17] , taken together with the previous results, suggest that tau hyperphosphorylation and primary neurodegeneration may occur independently of NFT formation, while the Wnt signaling pathway down-stream of GSK-3h may modulate tau-induced neurodegeneration or at least widespread NFT formation [17] .
These Drosophila tau models faithfully replicated several features of human tauopathies, including adult onset, progressive neurodegeneration, accumulation of abnormal tau (although not necessarily as NFTs) and early death. Further analysis of the existing fly tau models may determine the extent to which the different results from each model system are due to differences in expression levels, cell-type specificity of expression, and/or methods of phenotypic characterization. For both the fly and rodent models discussed below, interpretation of overexpression phenotypes and their comparison to disease-inducing mutations of resident human genes should be tempered with caution and appreciation of the innumerable differences between these model systems and their authentic human counterparts.
Xenopus
A cautionary tale is found in the following research that expressed many different forms of transgenic tau in Xenopus oocytes. The Xenopus maturation model was utilized to show the effects of tau in wild-type or mutant forms specifically on microtubule function. Delobel et al. [6] showed that wild-type four-repeat tau protein inhibited maturation in a concentration-dependent manner, whereas three-repeat tau had no effect. Of the seven four-repeat tau proteins with FTDP-17 mutations tested, five (G272V, DeltaK280, P301L, P301S, and V337M) failed to interfere significantly with oocyte maturation, demonstrating a greatly reduced ability to interact with microtubules. One mutant protein (R406W) almost behaved like wild-type tau, and one (S305N) inhibited maturation more strongly than wild-type tau. With the exception of R406W, wild-type tau and all the mutants studied were similarly phosphorylated during the Xenopus oocyte maturation, and this was independent of their effects on this process. Data obtained with R406W and S305N may be related to charge changes (phosphorylation and basic amino acids). Thus, FTDP-17 mutations had variable effects on microtubules in an intact cell situation, which underlines some of the interpretive dilemmas inherent in the use of models systems no matter how manipulable or powerful [6] .
Mice
Several mouse models of tauopathy have been developed that exhibit some of the pathological changes and even some phenotypic manifestations observed in human tauopathies, although interpretations of the findings in each of these models have their associated caveats.
Mice produce a homolog of tau, which is a microtubule binding protein that confers stability upon the cytoskeleton. The murine homolog of tau, however, is spliced only into the 4R isoforms in the adult murine brain, whereas human tau, as stated, is spliced into six isoforms evenly distributed between three microtubule binding repeat (3R) and four microtubule binding repeat (4R) isoforms that are expressed in the adult human brain [9] . Some models detailed below ablate the mouse tau gene and thus the mice produce only human tau, while others insert the human tau gene but leave the endogenous murine gene intact. Thus, these model systems differ with respect to the presence of different ratios of mouse and human tau isoforms, which complicates interpretation of findings in each of them. Many models also have cloned tau transgenes that produce solely one isoform, which can further complicate comparisons between model systems. In addition to the splicing ratio difference, the Nterminal domain of the mouse tau includes 14-amino-acid differences when compared to the human tau [19, 34] .
Gotz et al. [10] cloned the longest human brain tau isoform (4R subtype) under the control of the human Thy-1 promoter into a wild-type mouse background. As is generally found in AD, the transgenic human tau protein was present in the murine nerve cell bodies, axons and dendrites. In the NFTs associated with AD, tau is hyperphosphorylated and becomes insoluble. The transgenic human tau protein in the mouse brain was phosphorylated at sites that are hyperphosphorylated in paired helical filaments found in brains with AD type pathology. As the study did not find NFTs and did not show changes in tau solubility, the researchers concluded that the phosphorylation and low levels of accumulation were pretangle changes that precede full-blown tau neurofibrillary pathology associated with AD [11] .
The shortest human brain isoform of tau has been utilized in two studies. The first (Brion et al. [4] ) found no NFTs in animals up to 19 months of age and again attributed findings to a pre-tangle stage of neurofibrillary pathology. In this study, human transgenic tau remained abundant in cell bodies and dendrites of a subset of neurons in the adult, while the endogenous murine tau gradually decreased during development. This somatodendritic transgenic human tau was immunoreactive with antibodies specific for tau phosphoisoforms that are associated with AD and PHF or NFT inclusions. The authors also found a few astrocytes expressing the transgenic tau were strongly immunoreactive with antibodies to additional tau phosphorylation sites. The transgenic tau was also detected on microtubules in axons and in dendrites but not in cell bodies in astrocytes [4] .
In another study of the same year, Ishihara et al. [14] expressed the shortest isoform of tau in a wild-type background and studied these mice at 3 and 12 months of age. These mice acquired age-dependent CNS pathology similar to FTDP-17 and Gaum amytrophic lateral sclerosis (ALS) or the Guam ALS/Parkinsonism dementia comples (ALS/PDC), including insoluble, hyperphosphorylated tau and argyrophilic intraneuronal inclusions formed by tauimmunoreactive filaments, though these could not be unmistakably defined as NFTs. The inclusions could not be detected by specific histochemical stains such as Thioflavin S and Congo red that bind crossed h-pleated structures. The inclusions also contained a mixture of tau, neurofilament, and tubulin-immunoreactive straight filaments from 10 to 20 nm in diameter. These tau inclusions were stained by the Bodian silver method, though they were not silver-impregnated by the Gallyas method, which detects most NFTs in human tauopathies. Tau inclusions were present in cortical and brainstem neurons and were most abundant in spinal cord neurons. Here, the inclusions were associated with axon degeneration, diminished numbers of microtubules, and reduced axonal transport in ventral roots, as well as spinal cord gliosis and motor weakness. These were the first transgenic mice to recapitulate key features of human tauopathies including motor weakness, an important phenotypic feature Guam ALS and ALS/PDC [14] . This tauopathy model was followed up in later studies (Ishihara et al. [14] ) utilizing the same mice at 12 to 24 months of age to examine the impact of the aging process on transgenic mice and thus reflects the late-onset nature of human neurodegenerative tauopathies. In this study of these aged mice, the fibrillary tau lesions that were observed before had matured into structures that exhibited the morphology, immunohistochemical properties, and histochemical profile of true AD-like tangles within cortical neurons. Indeed, both Congo red and the Gallyas method stained the filamentous inclusions in the aged mice similarly to the brains of AD cases. The inclusions were composed entirely of straight tau filaments, as opposed to PHFs. These inclusions were not immunoreactive to antibodies to either tubulin or neurofilament. While the mouse endogenous tau remained mostly soluble in these mice, increasing amounts of insoluble tau paralleled the accumulation of congophilic tau detected in the CNS of these mice. This aging model is particularly interesting in that it recapitulates the progression of tau inclusions to insoluble, filamentous, Gallyas-positive NFTs over time (Fig. 2) [15] .
The previous studies all studied only one tau human isoform in isolation and within the background of endogenous, wild-type murine tau. However, human brains produce six alternately spliced forms of tau. To examine the normal cellular function of tau and its role in pathogenesis, Duff et al. [7] created transgenic mice that overexpressed a tau transgene derived from a human PAC that contains the coding sequence, intronic regions, and regulatory regions of the human gene, deemed 8c mice. All six isoforms of human tau were represented in the transgenic mouse brain at the mRNA and protein level. The human tau protein localized to neurites and synapses but was absent from cell bodies. Tauimmunoreactive axonal swellings were found in the spinal cords of the mice, which correlated with a hind-limb abnormality, but there were no other neuropathological abnormalities and no NFTs were seen [7] .
Recently, Andorfer et al. [1] produced a mouse model system that produces all six human isoforms of tau in a murine tau knockout background, thus ensuring that all tau produced is from the human tau gene and not from the endogenous tau gene. The authors termed this system htau mice and studied them for up to 13 months. Tau 3R isoforms and 4R isoforms are produced in approximately equivalent amounts in htau mice. The htau mice were generated by crossing 8c mice detailed above with murine tau knockout mice. While in young htau mice (6 weeks old), phospho-tau reactivity was high in axons but negligible in the cell bodies of the hippocampi, human tau isoforms accumulated in cell bodies by 3 months of age and increased with further aging. By 9 months of age, inclusions similar to NFTs were visible. Tau aggregation occurred in the cell bodies of cortical and pyramidal hippocampal cells that were similar to that seen in AD cases. Of particular interest in this study is that the majority of the tau pathology in htau mice was located in the neocortex and hippocampus and was minimal in the brain stem and spinal cord, but there were no gross motor or behavioral disturbances in htau mice [1] .
The preceding tauopathy mouse models all examine the effect of tau on neurons and the CNS. However, tauopathies are characterized by not only by widespread CNS neuronal involvement but also by glial tau pathologies. Higuchi et al. [13] generated tau transgenic mice that modeled neurodegeneration with glial tau lesions. While no neuronal tau aggregates were detected, older mice developed Thioflavin Sand Gallyas-positive glial tau pathology similar to astrocytic plaques observed in the human tauopathy corticobasal degeneration (CBD). Tau-immunoreactive and Gallyas-positive oligodendroglial coiled bodies (similar to those found in CBD and PSP cases), glial degeneration, and motor deficits were associated with age-dependent accumulations of insoluble, hyperphosphorylated human tau and tau immunopositive filaments in degenerating glial cells. Thus, taupositive glial lesions similar to human tauopathies occur in these tau transgenic mice, and these pathologies were associated with glial and axonal degeneration [13] . These tau transgenic mouse models also recapitulate some aspects of Guam ALS/PDC [34] ).
Since familial tauopathies such as FTDP-17 are associated with pathological mutations in the tau gene, either near splice sites that change the relative frequency of the tau isoforms or missense mutations that may affect microtubule binding, the pathogenicity of these various mutants of tau has been studied in a number of different transgenic mouse models and these studies generally show that a more severe neurodegenerative phenotype occurs as summarized below.
The V337M missense mutation of tau causes hereditary FTDP-17. Patients with this mutation have PHFs and/or straight filaments that consist of all six alternately spliced tau isoforms, and these filaments are indistinguishable from those seen in the brains of AD patients. Tanemura et al. [32] developed a transgenic mouse expressing mutant human tau that includes the V337M missense mutation. V337M transgenic mice produced hippocampal tau aggregations that resembled NFTs in human neurodegenerative diseases, including features such as thioflavin-S staining and con-gophilia. In addition to the accumulation of phosphorylated tau, neurons exhibited morphological abnormalities including irregularly shaped profiles. Behavioral differences between the V337M mice and wild-type mice were attributed to these pathologies [32] .
The R406W missense tau mutation in FTDP-17 kindreds causes a familial tauopathy with AD-like progressive memory loss and personality changes, but there are no Ah plaques. This suggests that some behavioral symptoms of AD can be induced by tau pathology alone and that Ah plaques are not obligatory mediators of these behavioral impairments. The R406W exonic mutation is constitutively expressed in all six isoforms of tau produced in the human brain and result in NFTs similar to those found in AD and other tauopathies. Tatebayashi et al. [33] found that expression in transgenic mice of even modest levels of the longest human tau isoform that included the R406W mutation resulted in congophilic, hyperphosphorylated tau inclusions in forebrain neurons that appeared as early as 18 months of age. Indeed, the mutant tau was robustly expressed in the forebrain region, but only weakly expressed in the cerebellum and brainstem. As expected, these tau inclusions were composed of both mutant and endogenous wild-type tau because the murine tau gene was not ablated. The tau inclusions also were associated with disruption of microtubules and straight tau filaments were recovered from Sarkosyl-insoluble fractions from only the brains of aged transgenic mice. Behaviorally, aged R406W transgenic mice had memory impairment without sensorimotor deficits [33] .
The most common mutation associated with FTDP-17 is the P301L missense mutation [30] . This exonic mutation does not affect the relative ratio of 3R/4R tau but appears to promote the self-assembly of mutant tau into filaments and tangles. Lewis et al. [21] created a line of transgenic mice (called JNPL3) that expressed 4R human tau with the P301L missense mutation. These transgenic mice developed NFTs with progressive motor disturbance, and they became moribund shortly thereafter (Fig. 3) . This phenotype occurred as early as 6.5 months of age in hemizygous animals and at 4.5 months in homozygotes. NFT formation in the JNPL3 mice was age-and gene-dose-dependent. NFTs and Pick-body-like neuronal lesions were widespread in the brain and spinal cord. Increasing insolubility and hyperphosphorylation of tau paralleled the increasing observed NFTs. Areas of the brain with the most NFTs also had reactive gliosis. The severe phenotype observed in the JNPL3 mice was surprising because the transgenic P301L tau was expressed at levels comparable to that of endogenous murine tau. Since earlier studies utilizing wildtype transgenic tau expressed the transgene at much higher levels than did the JNPL3 mice, the severe phenotype observed primarily is due to the P301L mutation [21] . Sahara et al. [26] biochemically examined the progression of the disease seen in JNPL3 mice. Brain homogenate from these mice was fractionated biochemically to determine whether the development of aggregated tau from soluble tau involves an intermediate stage. Homogenates from mice of different ages were separated into buffersoluble (S1), sarkosyl-and salt-extractable (S2) and sarkosyl-insoluble pellet (P3) fractions, and analyzed for human tau distribution, phosphorylation and filament formation. The more soluble S1 and S2 fractions contained lower molecular weight tau species, though the S2 fraction also included 64-kDa (higher molecular weight) tau. The level of insoluble tau in the P3 fraction increased in an agedependent manner and correlated with the soluble tau concentration. The higher molecular weight tau was predominantly the transgenic human tau protein, rather than the endogenous murine tau, and was phosphorylated at multiple sites. Most of these sites were phosphorylated to a lesser extent in S2 than in the insoluble P3 fractions. Tau polymers were detected in P3 fractions from 3-month and older female JNPL3 mice, but not in non-transgenic controls. The results suggest that tau in S2 represents an intermediate from which insoluble tau is derived, and that phosphorylation is associated with filament formation and/ or stabilization [26] .
Each of the previous studies has investigated the effect of either transgenic wild-type tau or tau with a single, pathological mutation. However, several different mutations have been linked to familial FTDP-17 or other tauopathies, and Lim et al. [22] cloned several tau gene mutations into a single, super-pathogenic transgene to model multiple consequences of the resulting tau abnormalities [30] . Ultrastructural analysis of mutant tau -positive neurons revealed pretangle-like structures of the cytoskeleton, with tau filaments and increased numbers of lysosomes displaying aberrant morphology similar to lysosomes found in AD. Alterations in lysosomal activity were analyzed and confirmed utilizing the marker acid phosphatase. Lysosomal activity was increased in both transgenic mice and transfected neuroblastoma cells, which may have been a result of the increased expression of transgenic tau, though lysosomal aberrations are not generally observed in tau transgenic mice. Thus, expression of this multiply-mutated tau protein provoked significant lysosomal aberrations, but it is unclear if this is a factor in tauopathies [22] .
Though the papers detailed above are relevant models for familial tauopathies, many common neurodegenerative diseases such as AD involve tau inclusions and perturbations but not primary, pathogenic mutations in the tau gene. Thus, Ah plaques and tau NFTs are defining neuropathological hallmarks of AD, but their pathophysiological roles are unclear. In an important study, Gotz et al. [10] injected a tau transgenic mouse with an exogenous source of Ah42, thus studying the effects of both of these implicated proteins. The authors injected synthetic Ah42 fibrils into the sensory cortices and hippocampi of P301L mutant tau transgenic mice, and this caused a synergistic response between Ah and tau such that the authors found fivefold increases in the numbers of NFTs in cell bodies within the amygdala from where neurons project to the injection sites. The observed NFTs were composed of twisted filaments and occurred in 6-month-old mice as early as 18 days after Ah42 injections. While previous studies detailed above had shown that P301L transgenic mice readily develop NFTs [21] , this seeming synergy was an important advance in the interactions of proteins that do not exist in isolation in the disease state [10] .
Tau is a microtubule binding protein that interacts not only with the cytoskeleton but also with other proteins implicated in neurodegenerative disease. For example, when cells are cotransfected with human tau and mutants of presenilin-1 (PS1), a gene commonly mutated in early-onset, hereditary AD, tau forms complex with PS1 and kinases (i.e. GSK-3h) found in the human brain and is increasingly phosphorylated. To study these phenomena in more detail, Boutajangout et al. [3] crossed transgenic mice that express the shortest isoform of human tau (0N3R) described above [4] with a strain of mice that carried a transgene for the familial AD M146L mutant of PS1. In these doubly transgenic mice, an increase in tau phosphorylation was observed, but no NFTs were found, and additional studies are needed to elucidate interactions between mutant of PS1 and human tau to resulting NFTs with neurodegeneration [3] .
To further explore interactions of tau and Ah in neurodegeneration, Lewis et al. [21] created mice that produced both the P301L mutant of human tau, JNPL3 mice [21] and mutant APP protein [20] . The resulting double mutant (tau/ APP) progeny and the mutant-APP parental strain developed Ah deposits at the same age, thus there was no effect of tau on Ah pathology. However, relative to parental strain of P301L tau JNPL3 mice, the double mutants exhibited substantially enhanced NFTs in the limbic system and olfactory cortex. These results support the hypothesis that tau and Ah may interact pathologically in AD during disease onset or progression [20, 21] .
More recently, Oddo et al. [25] combined three transgenes, mutant PS1(M146V), mutant APP(Swe), and mutant tau(P301L), in one line of triple transgenic mice (3xTg-AD). These 3xTg-AD mice progressively develop amyloid plaques and NFTs. Synaptic dysfunction, including longterm potentiation deficits, occurred in an age-related manner but before plaque and tangle pathology emerged. Deficits in long-term synaptic plasticity correlated with the accumulation of intraneuronal Ah. This study links the pathogenic role of intraneuronal Ah with synaptic plasticity. The recapitulation of salient features of AD pathology in these mice will help elucidate the relationship between Ah, synaptic dysfunction, and NFTs in AD [25] .
Hyperphosphorylated tau filaments are often found in brain of patients suffering from tauopathies. The responsible kinases operating in vivo in neurons remain to be identified. Spittaels et al. [31] demonstrated that GSK-3h phosphorylates tau in cerebral neurons in vivo in adult GSK-3h and GSK-3hÂhuman tau40 transgenic mice. Co-expression of GSK-3h reduced the number of axonal dilations and alleviated the motor impairment that was typical for single htau40 transgenic animals. Although more hyperphosphorylated protein tau was available, neither an increase in insoluble protein tau aggregates nor the presence of PHFs or tangles was observed, thereby leaving unresolved how tau hyperphosphorylation contributes to tangle formation [31] .
Conclusions
Tauopathies such as FTDP-17 and PSP, wherein tau pathologies are the dominant lesions, and other disorders such as AD that are defined by tau tangles and fibrillar deposits of Ah rank among some of the most severe and common neurodegenerative diseases [19] . While the range of transgenic animal models of the brain abnormalities in these disorders spans the phylogenetic tree from very simple invertebrates such as C. elegans through more complex invertebrates such as Drosophila to mice, many of these model systems have been developed only within the past few years and they have yet to be fully exploited to elucidate mechanisms of disease pathogenesis and for drug discovery efforts. Each of these animal models has strengths and disadvantages, and each must be carefully scrutinized before any conclusions can be drawn about human neurodegenerative disease. At the very least, each offers relevant information that can be utilized as simplified models for human tauopathies, and together they are likely to accelerate efforts to elucidate the role of tau in neurodegeneration and to develop better therapies to treat these disorders.
